https://www.mscare.org/genentechs-fenebrutinib-confirms-its-potential-as-first-and-only-btk-inhibitor-for-relapsing-and-primary-progressive-ms-in-third-positive-phase-iii-study-fenhance-1/
Genentech’s Fenebrutinib Confirms Its Potential as First and Only BTK Inhibitor for Relapsing and...
Consortium of Multiple Sclerosis Centers
first and only